2123 Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer

Authors :: Kentaro Yamazaki
A. Lee Cohn
Rocio Garcia-Carbonero
F. Nasroulah
Shao-Chun Chang
David Ferry
L. Yang
Ling Gao
P. García-Alfonso
Takayuki Yoshino
Philip Clingan
Sara Lonardi
E. Van Cutsem
David Craig Portnoy
Radka Obermannova
J. Polikoff
Jana Prausová
G. Bodoky
J. Tabernero
T. Eliade Ciuleanu
Source :: European Journal of Cancer. 51:S372
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Colorectal cancer
business.industry
Phases of clinical research
medicine.disease
Ramucirumab
Double blind
Internal medicine
medicine
Line (text file)
business
Exposure response

Full Text Access

Tools